Cargando…

Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial

The botanical product silymarin, an extract of milk thistle, is commonly used by patients to treat chronic liver disease and may be a treatment for NASH due to its antioxidant properties. We aimed to assess the safety and efficacy of higher than customary doses of silymarin in non-cirrhotic patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Navarro, Victor J., Belle, Steven H., D’Amato, Massimo, Adfhal, Nezam, Brunt, Elizabeth M., Fried, Michael W., Reddy, K. Rajender, Wahed, Abdus S., Harrison, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752871/ https://www.ncbi.nlm.nih.gov/pubmed/31536511 http://dx.doi.org/10.1371/journal.pone.0221683

Ejemplares similares

Correction: Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial
por: Navarro, Victor J., et al.
Publicado: (2019)

Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C
por: Reddy, K Rajender, et al.
Publicado: (2012)

Silymarin and management of liver function in non-alcoholic steatohepatitis: a case report
por: Hashem, Ahmed
Publicado: (2023)

Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis
por: Marin, Veronica, et al.
Publicado: (2017)

Role of silymarin in the management of deranged liver function in non-alcoholic steatohepatitis: a case report
por: Lee, Yeong Yeh, et al.
Publicado: (2023)

In the non-cirrhotic stage of nonalcoholic steatohepatitis, angioarchitecture of portal veins and lobular architecture are maintained
por: Hano, Hiroshi, et al.
Publicado: (2013)

Silymarin in the management of liver enzyme activity in steatohepatitis: a case report
por: Torre, Aldo
Publicado: (2023)

The effects of concurrent treatment of silymarin and lactulose on memory changes in cirrhotic male rats
por: Ghobadi Pour, Mozhgan, et al.
Publicado: (2020)

Effects of Pentoxifylline on Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial in Iran
por: Baniasadi, Nadieh, et al.
Publicado: (2015)

Impact of Type 2 Diabetes on Oncologic Outcomes of Hepatocellular Carcinomas in Non-Cirrhotic, Non-alcoholic Steatohepatitis: a Matched-Pair Analysis
por: Billeter, Adrian T., et al.
Publicado: (2020)

Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: Analysis of isolated hepatic stellate cells
por: KIM, MINA, et al.
Publicado: (2012)

Glypican-3-Expressing Hepatocellular Carcinoma in a Non-Cirrhotic Patient with Nonalcoholic Steatohepatitis: Case Report and Literature Review
por: Ismail, Mona H.
Publicado: (2010)

Metabolic effect of berberine–silymarin association: A meta‐analysis of randomized, double‐blind, placebo‐controlled clinical trials
por: Fogacci, Federica, et al.
Publicado: (2019)

Silymarin: An option to treat non-alcoholic fatty liver disease
por: Colica, Carmela, et al.
Publicado: (2017)

In Vivo Efficacy Study of Milk Thistle Extract (ETHIS-094™) in STAM™ Model of Nonalcoholic Steatohepatitis
por: Pais, Pilar, et al.
Publicado: (2014)

Prognostic Value of Simple Non-Invasive Tests for the Risk Stratification of Incident Hepatocellular Carcinoma in Cirrhotic Individuals with Non-Alcoholic Fatty Liver Disease
por: Armandi, Angelo, et al.
Publicado: (2023)

Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease
por: Hartl, Lukas, et al.
Publicado: (2021)

Silymarin for the Prevention of Contrast-Induced Nephropathy: A Placebo-Controlled Clinical Trial
por: Sedighifard, Zohreh, et al.
Publicado: (2016)

Fructose and Non-Alcoholic Steatohepatitis
por: Roeb, Elke, et al.
Publicado: (2021)

Statins in Non-alcoholic Steatohepatitis
por: Torres-Peña, Jose D., et al.
Publicado: (2021)

A Double-Blind, Randomized Placebo-Controlled Trial of Probiotic Lactobacillus casei Shirota in Stable Cirrhotic Patients
por: Macnaughtan, Jane, et al.
Publicado: (2020)

Silymarin, Olibanum, and Nettle, A Mixed Herbal Formulation in the Treatment of Type II Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial
por: Khalili, Nahid, et al.
Publicado: (2017)

The effect of silymarin on liver enzymes and antioxidant status in trauma patients in the intensive care unit: a randomized double blinded placebo-controlled clinical trial
por: Mirzaei, Ehsan, et al.
Publicado: (2021)

Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail
por: Sharma, Mithun, et al.
Publicado: (2021)

Silymarin and diabetic nephropathy
por: Rafieian-Kopaie, Mahmoud, et al.
Publicado: (2012)

Hepatocellular Carcinoma Arising in Non-Cirrhotic Haemochromatosis
por: Thompson, N. P., et al.
Publicado: (1995)

Causes and Management of Non-cirrhotic Portal Hypertension
por: Gioia, Stefania, et al.
Publicado: (2020)

Liver Fibrogenesis in Non-Alcoholic Steatohepatitis
por: Bian, Zhaolian, et al.
Publicado: (2012)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

Therapeutic approaches for non-alcoholic steatohepatitis
por: Van Gaal, Luc F., et al.
Publicado: (2021)

Nitro-oxidative stress, VEGF and MMP-9 in patients with cirrhotic and non-cirrhotic portal hypertension
por: MUTI, LEON ADRIAN, et al.
Publicado: (2015)

The Effect of Mycotoxins and Silymarin on Liver Lipidome of Mice with Non-Alcoholic Fatty Liver Disease
por: Bechynska, Kamila, et al.
Publicado: (2021)

Non-cirrhotic Non-Wilsonian degeneration in antiphospholipid syndrome: Association or chance
por: Kumar, Sunil, et al.
Publicado: (2022)

Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid
por: Yoo, Wonbeak, et al.
Publicado: (2017)

Protective effect of rutin in comparison to silymarin against induced hepatotoxicity in rats
por: Reddy, M. Kasi, et al.
Publicado: (2017)

The Role of Serum Procalcitonin Levels in Predicting Ascitic Fluid Infection in Hospitalized Cirrhotic and Non-cirrhotic Patients
por: Cekin, Yesim, et al.
Publicado: (2013)

Differential reactivation of fetal/neonatal genes in mouse liver tumors induced in cirrhotic and non-cirrhotic conditions
por: Chen, Xi, et al.
Publicado: (2015)

Prognosis of critically ill cirrhotic versus non-cirrhotic patients: a comprehensive score-matched study
por: Fu, Chung-Ming, et al.
Publicado: (2014)

A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis
por: Palmer, Melissa, et al.
Publicado: (2018)

Bacteriologic study of cirrhotic patients with non-neutrocytic ascites
por: Dabiri, Hossein, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1dsp99badb0tb22s9c5ot0moh7